Lederer & Associates Investment Counsel Amgen Inc Transaction History

Lederer & Associates Investment Counsel

$142 Million
Q3 2024

A detailed history of Lederer & Associates Investment Counsel transactions in Amgen Inc stock. As of the latest transaction made, Lederer & Associates Investment Counsel holds 6,959 shares of AMGN stock, worth $1.83 Million. This represents 1.58% of its overall portfolio holdings.

Number of Shares

6,959

Previous 7,053 1.33%

Holding current value

$1.83 Million

Previous $2.2 Million 1.72%

% of portfolio

1.58%

Previous 1.59%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$309.38 - $337.38 $29,081 - $31,713	-94 Reduced 1.33%	6,959 $2.24 Million
Q2 2024 Aug 02, 2024	SELL	$262.75 - $319.31 $91,962 - $111,758	-350 Reduced 4.73%	7,053 $2.2 Million
Q1 2024 Apr 29, 2024	SELL	$268.87 - $324.56 $465,413 - $561,813	-1,731 Reduced 18.95%	7,403 $2.11 Million
Q4 2023 Jan 19, 2024	SELL	$255.7 - $288.46 $54,464 - $61,441	-213 Reduced 2.28%	9,134 $2.63 Million
Q3 2023 Oct 23, 2023	SELL	$218.65 - $271.46 $15,961 - $19,816	-73 Reduced 0.77%	9,347 $2.51 Million
Q2 2023 Aug 04, 2023	SELL	$214.27 - $253.37 $5,999 - $7,094	-28 Reduced 0.3%	9,420 $2.09 Million
Q1 2023 Apr 17, 2023	SELL	$225.79 - $275.2 $19,869 - $24,217	-88 Reduced 0.92%	9,448 $2.28 Million
Q4 2022 Jan 12, 2023	SELL	$229.03 - $291.01 $76,037 - $96,615	-332 Reduced 3.36%	9,536 $2.51 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $38,382 - $43,288	-171 Reduced 1.7%	9,868 $2.22 Million
Q2 2022 Aug 09, 2022	SELL	$230.71 - $256.74 $312,842 - $348,139	-1,356 Reduced 11.9%	10,039 $2.44 Million
Q1 2022 May 24, 2022	SELL	$219.27 - $242.57 $33,329 - $36,870	-152 Reduced 1.32%	11,395 $2.76 Million
Q4 2021 Jan 24, 2022	SELL	$198.88 - $227.6 $26,649 - $30,498	-134 Reduced 1.15%	11,547 $2.6 Million
Q3 2021 Oct 22, 2021	BUY	$212.27 - $248.7 $343,028 - $401,899	1,616 Added 16.06%	11,681 $2.48 Million
Q2 2021 Jul 23, 2021	SELL	$233.58 - $259.14 $50,219 - $55,715	-215 Reduced 2.09%	10,065 $2.45 Million
Q1 2021 Apr 19, 2021	BUY	$221.91 - $258.6 $9,098 - $10,602	41 Added 0.4%	10,280 $2.56 Million
Q4 2020 Jan 25, 2021	SELL	$216.38 - $257.67 $16,012 - $19,067	-74 Reduced 0.72%	10,239 $2.35 Million
Q3 2020 Jan 13, 2021	BUY	$234.65 - $260.95 $10,324 - $11,481	44 Added 0.43%	10,313 $2.62 Million
Q2 2020 Jul 14, 2020	SELL	$197.81 - $242.74 $12,857 - $15,778	-65 Reduced 0.63%	10,269 $2.42 Million
Q1 2020 Apr 20, 2020	BUY	$182.24 - $241.7 $29,705 - $39,397	163 Added 1.6%	10,334 $2.1 Million
Q4 2019 Feb 07, 2020	SELL	$189.21 - $243.2 $486,080 - $624,780	-2,569 Reduced 20.16%	10,171 $2.45 Million
Q3 2019 Oct 07, 2019	SELL	$174.11 - $208.62 $56,585 - $67,801	-325 Reduced 2.49%	12,740 $2.47 Million
Q2 2019 Jul 19, 2019	BUY	$166.7 - $195.41 $66,680 - $78,164	400 Added 3.16%	13,065 $2.41 Million
Q1 2019 Apr 12, 2019	SELL	$180.87 - $203.88 $18,991 - $21,407	-105 Reduced 0.82%	12,665 $2.41 Million
Q4 2018 Jan 25, 2019	SELL	$178.4 - $208.25 $67,792 - $79,135	-380 Reduced 2.89%	12,770 $2.49 Million
Q3 2018 Oct 22, 2018	BUY	$185.29 - $208.89 $57,439 - $64,755	310 Added 2.41%	13,150 $2.73 Million
Q2 2018 Jul 27, 2018	SELL	$166.05 - $186.51 $53,966 - $60,615	-325 Reduced 2.47%	12,840 $2.37 Million
Q1 2018 Apr 09, 2018	SELL	$169.43 - $198.0 $23,889 - $27,918	-141 Reduced 1.06%	13,165 $2.24 Million
Q4 2017 Jan 11, 2018	BUY	$168.79 - $188.59 $46,754 - $52,239	277 Added 2.13%	13,306 $2.31 Million
Q3 2017 Oct 13, 2017	BUY	$167.29 - $191.0 $2.18 Million - $2.49 Million	13,029	13,029 $2.43 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $140B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lederer & Associates Investment Counsel, based on Form 13F filings with the SEC.

News

Stay updated on Lederer & Associates Investment Counsel with notifications on news.

Account

Lederer & Associates Investment Counsel Amgen Inc Transaction History